Skip to Content
Merck
CN

SML0050

CGP 37849

≥98% (HPLC)

Synonym(s):

(3E)-2-Amino-4-methyl-5-phosphono-3-pentanoic acid

Sign In to View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C6H12NO5P
CAS Number:
Molecular Weight:
209.14
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: ≥2 mg/mL (warmed)

storage temp.

2-8°C

SMILES string

C\C(CP(O)(O)=O)=C/C(N)C(O)=O

InChI

1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+

InChI key

BDYHNCZIGYIOGJ-DUXPYHPUSA-N

Application

CGP 37849 may be used in NMDA-mediated cell signaling studies.

Biochem/physiol Actions

CGP 37849 induces phencyclidine-like behavioral syndrome in amygdala-kindled rats that includes ataxia, locomotion and stereotypies.
CGP 37849 is a potent orally active competitive NMDA antagonist and anticonvulsant.
Potent orally active competitive NMDA antagonist and anticonvulsant.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Y Gemperle et al.
Neuroscience, 117(3), 681-695 (2003-03-06)
The mode of action of the antipsychotic drugs clozapine, haloperidol and iloperidone was investigated in layer V of prefrontal cortex slices using extracellular field potential, intracellular sharp-electrode as well as whole-cell voltage clamp recording techniques. Intracellular investigations on a broad
K Wedzony et al.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 56(2), 205-221 (2005-06-30)
Malfunction of glutamatergic neurotransmission in postnatal period is considered to be a risk factor for development of schizophrenia. Thus, the present study investigates the impact of NMDA receptor blockade in the postnatal period on the density of tyrosine hydroxylase immunoreactive
Krzysztof Wedzony et al.
Pharmacological reports : PR, 60(6), 856-864 (2009-02-13)
Postnatal hypofunction of N-methyl-D-aspartate (NMDA) receptors leads to several behavioral deficits in adult rats resembling deficits typical of schizophrenia-like deficits of sensorimotor gating. Thus far, it is not known whether the above disruptions are sensitive to neuroleptic drugs. In order
K Wedzony et al.
Neuroscience, 153(4), 1370-1379 (2008-04-25)
The malfunction of glutamatergic neurotransmission in the neonatal or postnatal periods may be a risk factor for the appearance of neuroanatomical, neurochemical or functional changes that are characteristic of schizophrenia. Thus, the present study was undertaken to investigate whether blockade
Romana Slamberová et al.
European journal of pharmacology, 516(1), 10-17 (2005-05-21)
Epileptic afterdischarges elicited by stimulation of sensorimotor cortex were chosen to test anticonvulsant effects of NMDA receptor antagonists in developing rats (12, 18 and 25 days old) with implanted electrodes. Afterdischarges were elicited four times with 10-min intervals in the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service